

ASX ANNOUNCEMENT

BLOCK TRADE INTRODUCES NEW INSTITUTIONAL INVESTORS TO VIT SHARE REGISTER

22 MAY 2023

Melbourne, Australia – Vitura Health Limited (ASX: VIT) (Company) advises that a block trade of 18,750,000 shares in the Company (Block Trade Shares) has been executed by Director Guy Rothwell Headley, a substantial shareholder in the Company and co-founder of CDA Health Pty Ltd that was merged to form Vitura.

Mr. Headley offered the Block Trade Shares to two institutional investors at a sale price of \$0.32 per Block Trade Share, with settlement expected to occur on or around Tuesday, 23 May 2023. The transaction occurred in consultation with the Company. The transaction represents approximately 14% of Mr. Headley's overall beneficial shareholding and is the first time he has sold shares in the Company. The Block Trade Shares sold represent approximately 3.4% of the Company's total outstanding shares.

Mr. Headley has expressed in writing to the Company that, following the sale of the Block Trade Shares, he has no present intention to sell any further shares in the Company in the near future and will consult with the Company if that intention changes.

The Company looks forward to further institutionalising the Company's share register and increasing liquidity of the Company's shares.

** ENDS **

VITURA HEALTH LIMITED

ASX: VIT

PO Box 6168, South Yarra

Victoria 3141, Australia

VITURA.COM.AU

BHC'S
CANVIEW

CDA
CLINICS

CORTEXA

cannadoc



About Vitura Health Limited

Vitura Health Limited (formerly Cronos Australia Limited) is listed on the ASX.

- The Company, via its wholly owned subsidiaries, operates the following businesses:
 - Burleigh Heads Cannabis - operates the market leading prescriber, patient, pharmacy and supplier online platform, CanView, which sells and distributes 230+ product SKUs within Australia from over 30 international and domestic medicinal cannabis producers
 - CDA Clinics - undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis
- The Company owns 50% of Cortexa Pty Ltd, an incorporated joint venture with Canadian-based PharmAla Biotech (CSE:MDMA). Cortexa aims to be the leading supplier of psychedelics, GMP MDMA and GMP psilocybin, for research and therapeutic use in Australia
- The Company owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.
- See:
 - www.vitura.com.au
 - www.canview.com.au
 - www.burleighheadscannabis.com
 - www.cortexa.com.au
 - www.cdaclinics.com.au
 - www.cannadoc.com.au

Authorised by

Rodney Cocks, Chief Executive Officer and Executive Director

Contact

Vitura Health Limited

Rodney Cocks
Chief Executive Officer and Executive Director
1300 799 491
info@vitura.com.au

Media enquiries

Tim Fogarty
The Civic Partnership
+61 400 179 075
tim.fogarty@civicpartners.com.au

Forward-looking statements

This announcement includes forward-looking statements which may be identified by words such as 'anticipates', 'believes', 'expects', 'intends', 'may', 'will', 'could', or 'should' and other similar words that involve risks and uncertainties. These forward-looking statements are based on the Company's expectations and beliefs concerning future events as at the date of this announcement. Forward-looking statements are necessarily subject to risks, uncertainties and other factors, many of which are outside the control of the Company, which could cause actual results to differ materially from such statements. The Company makes no undertaking to update or revise the forward-looking statements made in this announcement to reflect any change in circumstances or events after the date of this announcement.